Navigation Links
Eisai/Pfizer's Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimer's Disease
Date:2/4/2008

rovide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

For each disease examined, Decision Resources' Treatment Algorithms Insight Series provides the following:

-- Qualitative diagnosis and referral patterns for the United States

based on thought leader input and guideline recommendations.

-- Quantitative treatment algorithms based on patient-level claims data

Product share (class and specific compound level) within each line

of therapy (1st, 2nd, 3rd line).

-- Practicing physician opinion on why specific drugs are chosen for

certain patient populations.

-- Discussion of key drug combinations (including add versus switch

patterns) by lines of therapy.

-- Progression of therapy from key 1st line products (e.g., initial

treatment with Lipitor to 2nd line, 3rd line; initial treatment with

Zocor to 2nd line, 3rd line).

-- Pathway to key therapies from previous therapies (e.g., how much

Avandamet use is preceded by metformin, Avandia, or both as single

products?).

-- Qualitative analysis of 2-year forecast incorporating practicing

physician sentiment towards upcoming launches, changes in

reimbursement, etc.

About Decision Resources

Decision Resources, Inc., (http://www.DecisionResources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information,
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
2. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
5. Breakthrough Opportunity for Improving Patient Health
6. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
7. Physicians Practice, Loma Linda Partner to Improve Patient Care in Southern California
8. Difficult to Treat Erectile Dysfunction Patients
9. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
10. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
11. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... , March 30, 2015  Multiple new research abstracts ... several important health factors. From their impact on colon ... positive effect on both gut health and vascular health, ... detail our latest understanding of walnuts, inner workings. Running ... , this annual meeting attracts an international audience ...
(Date:3/30/2015)... US-Australian drug discovery company, Novogen Ltd, (ASX:NRT; ... and Yale University, on March 27 released pre-clinical data ... as an oral presentation by Professor Gil Mor ... 62 nd Annual Scientific Meeting of the Society ... In both in vitro and ...
(Date:3/30/2015)... 30, 2015  Spherix Incorporated (Nasdaq: SPEX ... fostering and monetization of intellectual property, today provided ... 3:13-cv-03494-M and  Spherix v. Uniden , Case No. ... for the Northern District of Texas ... v. Verizon, Case No. 1:14-cv-00721-GBL-TCB, in the ...
(Date:3/30/2015)... 2015 Richmond Pharmacology nimmt ... Pharmacology ist das erste Zentrum weltweit, das in ... Hospital in London in ... Studienversuche an einem Patienten begonnen hat. Das Therapeutikum ... entwickelt (ATTR), einer seltenen Herz- und Nervenkrankheit. ...
Breaking Biology Technology:New Findings Support the Benefits of Eating Walnuts on Overall Health 2New Findings Support the Benefits of Eating Walnuts on Overall Health 3New Findings Support the Benefits of Eating Walnuts on Overall Health 4Yale University and Novogen Release Data on Cantrixil Mode of Action 2Yale University and Novogen Release Data on Cantrixil Mode of Action 3Yale University and Novogen Release Data on Cantrixil Mode of Action 4Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3
... N.J., March 18 Sopherion Therapeutics, LLC, a ... of anti-cancer therapies, announced that it completed enrollment ... liposomal doxorubicin (Myocet(TM)) in metastatic HER-2-overexpressing breast cancer. ... of Sopherion,s lead product in combination with the ...
... Troy, N.Y. Researchers at Rensselaer Polytechnic Institute ... copper nanorods, a key step for advancing integrated ... fuse together, or anneal, at about 300 degrees ... the nanorods ideal for use in heat-sensitive nanoelectronics, ...
... PLYMOUTH MEETING, Pa., March 17 /PRNewswire-Asia-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: ... for the fourth quarter and fiscal year ended,December 31, 2008. , ... -- Fourth quarter revenues increased to $36.6 million, ... fourth quarter of 2007., -- Non-GAAP operating income, ...
Cached Biology Technology:Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer 2Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer 3Slimmer, stickier nanorods give boost to 3-D computer chips 2BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 2BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 3BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 4BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 5BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 6BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 7BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 8BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 9BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 10BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 11BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 12
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/4stcg3/india_sensors ) ... Sensors Market Forecast and Opportunities 2020" report ... is projected to grow at a CAGR over ... industrial and healthcare sectors are the key application ... adoption of MEMS technology in sensors is growing ...
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Latin America . Annual estimates ...
(Date:3/17/2015)... , March 17, 2015 MedNet ... specializing in clinical study management systems, is pleased ... attendance at ARENA,s Outsourcing in Clinical Trials Southeast ... event provides an excellent forum for MedNet to ... and affordable software-as-a-service (SaaS) eClinical technology platform. ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... who contract gastroenteritis from drinking water contaminated with ... high blood pressure, kidney problems and heart disease in later ... Medical Journal . The findings underline the importance of ... for regular monitoring for those affected. It is estimated ...
... Physical activity promotes changes in the brain that ... of Alzheimer,s disease, according to a new study done ... Carson Smith, an assistant professor of health sciences, included ... gene for Alzheimer,s disease, and other healthy older adults ...
... Va. Since the Civil War, the stethoscope has been ... average doctor may be toting another valuable diagnostic tool: a ... professor of internal medicine at Eastern Virginia Medical School, believes ... years they will become commonplace," he predicts. Dr. Levitov, ...
Cached Biology News:E coli infection linked to long-term health problems 2Study shows importance of exercise for those at special risk for Alzheimer's 2Author predicts widespread acceptance of pocket-sized ultrasound machines 2
Human FADD Affinity Purified Polyclonal Ab...
Immunogen: Synthetic peptide based on the sequence: SPSSGPSLTADSMWR Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse Endoglin/CD105 Fluorescein MAb (Clone 209701)...
... Ac-DEVD-CHO is an ... activity. The concentration of ... caspase activity must be ... system. Ten micromolar inhibitor ...
Biology Products: